The company remains in a pre-revenue stage, reporting consistent quarterly operating losses of $2.3 million as of 2025Q2, driven primarily by sustained R&D expenditures.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 89K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | -89K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | - | - | - | - |
| Operating Expenses | 8.57M | 11.09M | 9.9M | 12.05M | 13.46M | 5.59M | 2.89M | 1.24M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.82M | 4.86M | 4.2M | 4.78M | 7.05M | 2.5M | 393K | 337K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 4.75M | 6.23M | 5.7M | 7.27M | 6.42M | 3.08M | 2.5M | 898K |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.57M | -11.09M | -9.9M | -12.05M | -13.55M | -5.59M | -2.89M | -1.24M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -11.95% | 17.82% | 11.09% | -142.56% | -93.46% | -133.85% | - |
| EBITDA | -8.55M | -11.07M | -9.88M | -12.03M | -13.46M | -5.58M | -2.88M | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -35.54% | -12.03% | 17.86% | 10.66% | -141.1% | -93.55% | - | - |
| D&A (Non-Cash Add-back) | 18.75K | 16K | 22K | 21K | 89K | 3K | 3K | 1.24M |
| EBIT | -8.57M | -11.13M | -9.9M | -9.66M | -12.32M | -2.89M | -2.83M | -1.22M |
| Net Interest Income | -88K | 13K | -309K | -372K | 76K | -1.15M | 61K | 13K |
| Interest Income | 0 | 13K | 2K | 178K | 91K | 0 | 61K | 18K |
| Interest Expense | 88K | 0 | 311K | 550K | 15K | 1.15M | 0 | 5K |
| Other Income/Expense | -88K | -40K | -308K | 1.94M | 1.21M | 1.55M | 60K | 13K |
| Pretax Income | -8.66M | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M | -2.83M | -1.22M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -8.66M | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M | -2.83M | -1.23M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | -2.74% | -8.96% | -1.02% | 18.1% | -205.37% | -42.89% | -130.48% | - |
| Net Income (Continuing) | -8.66M | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M | -2.83M | -1.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.34 | -0.44 | -0.55 | -0.83 | -1.07 | -0.23 | -0.51 | -0.22 |
| EPS Growth % | 28.57% | 20% | 33.73% | 22.43% | -365.22% | 54.9% | -131.82% | - |
| EPS (Basic) | - | -0.44 | -0.55 | -0.83 | -1.07 | -0.23 | -0.51 | -0.22 |
| Diluted Shares Outstanding | 25.4M | 25.48M | 18.6M | 13.64M | 11.51M | 10.86M | 5.52M | 5.45M |
| Basic Shares Outstanding | 25.4M | 25.48M | 18.6M | 13.64M | 11.51M | 10.86M | 5.52M | 5.45M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution
As indicated by recent financial disclosures, NeuroSense maintains a consistent R&D expenditure profile, with quarterly costs averaging approximately $1.5 million, reflecting the intensive capital requirements of ongoing clinical trial management and the manufacturing of PrimeC for study-related activities in a pre-revenue environment.
The company's cost structure is almost entirely composed of R&D and SG&A, with no offsetting revenue to mitigate the burn. This reliance on external funding to cover fixed operational costs suggests that any delay in clinical milestones could exacerbate the existing financial strain.
Based on the reported income statements, net income figures are frequently impacted by non-operating items and stock-based compensation, as seen in the 2023Q3 period where a temporary positive net income of $784,000 appeared despite the absence of any underlying commercial revenue generation.
Investors should monitor these fluctuations, as they do not represent operational profitability but rather accounting adjustments or non-recurring items. The volatility in EPS, ranging from -0.38 to 0.06, highlights the difficulty in assessing core performance during this developmental phase.
According to the latest quarterly filings, the company continues to report significant operating losses, with the 2025Q2 operating loss reaching $2.3 million, demonstrating that overhead and R&D costs are scaling without the support of a commercial revenue base to provide operating leverage.
The lack of revenue means that every dollar spent on SG&A and R&D directly increases the net loss, leaving no room for operational efficiency gains. This structure implies that the company remains entirely dependent on capital markets to sustain its current operating scale.
As reported in recent financial statements, the company's cash position has dwindled to approximately $166,000, which suggests a critical liquidity risk that may necessitate immediate dilutive financing to maintain the current trajectory of clinical development and administrative operations.
Short-term observers may focus on the extreme cash-to-burn ratio, which indicates that the company's runway is effectively exhausted. This situation warrants further investigation into the firm's ability to secure non-dilutive capital or strategic partnerships before the current cash reserves are fully depleted.
Quick answers to the most common questions about buying NRSN stock.
For fiscal year 2025, NeuroSense Therapeutics Ltd. (NRSN) reported total revenue of $0.0M.
NeuroSense Therapeutics Ltd. (NRSN) reported a net loss of $11.1M for the fiscal year ending 2025.